Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09DND
|
|||
| Drug Name |
Anti-GD2-CAR engineered T cells
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Neuroblastoma [ICD-11: 2D11.2] | Phase 1 | [1] | |
| Osteosarcoma [ICD-11: 2B51; ICD-9: 170] | Phase 1 | [1] | ||
| Sarcoma [ICD-11: 2A60-2C35; ICD-10: C81-C86; ICD-9: 202.8] | Phase 1 | [1] | ||
| Company |
National Cancer Institute (NCI)
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ganglioside GD2 (GD2) | Target Info | CAR-T-Cell-Therapy | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02107963) A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.